Detalhe da pesquisa
1.
Olgotrelvir as a Single-Agent Treatment of Nonhospitalized Patients with Covid-19.
NEJM Evid;
3(6): EVIDoa2400026, 2024 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38804790
2.
Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19.
Med;
5(1): 42-61.e23, 2024 Jan 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38181791
3.
Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19.
Med;
5(2): 169-171, 2024 Feb 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38340710